These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15615259)

  • 1. A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.
    Kinoshita T; Hotta T; Tobinai K; Kobayashi T; Ishizuka N; Tomonaga M; Sai T; Ohno Y; Kasai M; Ogura M; Mikuni C; Toki H; Sano M; Masaki Y; Ohtsu T; Matsuno Y; Takenaka T; Shirakawa S; Shimoyama M;
    Int J Hematol; 2004 Nov; 80(4):341-50. PubMed ID: 15615259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group.
    Cameron DA; White JM; Proctor SJ; Prescott RJ; Leonard RC; Angus B; Cook MK; Dawes PJ; Dawson AA; Evans RG; Galloway MJ; Harris AL; Heppleston A; Horne CH; Krajewski AS; Lennard AL; Lessells AM; Lucraft HH; MacGillivray JB; Mackie MJ; Parker AC; Roberts JT; Taylor PR; Thompson WD
    Eur J Cancer; 1997 Jul; 33(8):1195-201. PubMed ID: 9301442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
    Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
    Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
    Dreiher J; Shpilberg O; Raanani P; Chetrit A; Ben-Bassat I
    Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of VEPA/FEPP chemotherapy for aggressive lymphoma in elderly patients: Japan Clinical Oncology Group Study JCOG9203.
    Mizoroki F; Hirose Y; Sano M; Fukuda H; Tobinai K; Nakata M; Taniwaki M; Kawano F; Uozumi K; Sawada K; Fukuhara S; Nasu K; Ohno Y; Toki H; Togawa A; Kikuchi M; Hotta T; Shimoyama M;
    Int J Hematol; 2006 Jan; 83(1):55-62. PubMed ID: 16443554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
    Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
    Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG).
    Niitsu N; Okamoto M; Kuraishi Y; Nakamura S; Kodama F; Hirano M
    Eur J Haematol; 2000 Sep; 65(3):188-94. PubMed ID: 11007055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VB-CHEP chemotherapy regimen for aggressive non-Hodgkin's lymphomas.
    Yalçin S; Kars A; Ozişik Y; Tekuzman G; Ozyilkan O; Celik I; Barişta I; Güllü I; Güler N; Baltali E; Firat D
    Eur J Haematol; 1998 Oct; 61(4):261-5. PubMed ID: 9820633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide.
    Balzarotti M; Spina M; Sarina B; Magagnoli M; Castagna L; Milan I; Ripa C; Latteri F; Bernardi D; Bertuzzi A; Nozza A; Roncalli M; Morenghi E; Tirelli U; Santoro A
    Ann Oncol; 2002 Sep; 13(9):1341-6. PubMed ID: 12196358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
    Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
    J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL).
    Silingardi V; Federico M; Cavanna L; Avanzini P; Gobbi PG; Lombardo M; Carotenuto M; Frassoldati A; Pieresca C; Vallisa D
    Leuk Lymphoma; 1995 Apr; 17(3-4):313-20. PubMed ID: 8580801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Pfreundschuh M; Zwick C; Zeynalova S; Dührsen U; Pflüger KH; Vrieling T; Mesters R; Mergenthaler HG; Einsele H; Bentz M; Lengfelder E; Trümper L; Rübe C; Schmitz N; Loeffler M;
    Ann Oncol; 2008 Mar; 19(3):545-52. PubMed ID: 18065407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
    Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
    N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma.
    Wylie JP; Cowan RA; Radford JA; Deakin DP; Harris M; Wilkinson PM
    Clin Oncol (R Coll Radiol); 2000; 12(3):153-7. PubMed ID: 10942331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-escalation of CHOP in non-Hodgkin's lymphoma.
    Santoro A; Balzarotti M; Tondini C; Zanini M; Giardini R; Latteri F; Rampinelli I; Bufalino R
    Ann Oncol; 1999 May; 10(5):519-25. PubMed ID: 10416000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
    Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
    Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.